

Section 1: Issuer information	
Name of issuer	Rua Bioscience Limited
NZX ticker code	RUA
Class of financial product	Unlisted convertible note (convertible into ordinary shares)
ISIN (If unknown, check on NZX website)	NZRUA0004S1
Currency	NZ\$
Section 2: Capital change details	
Number issued/acquired/redeemed	Up to a maximum of 6,000,000 shares
Nominal value (if any)	\$150,000
Issue/acquisition/redemption price per security	\$0.025
Nature of the payment (for example, cash or other consideration)	\$150,000 cash
Amount paid up (if not in full)	Convertible note paid in full on issue, if converted will be converted to fully paid up ordinary shares
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) ¹	Rua currently has 339,441,705 ordinary shares on issue and 8,062,512 warrants. This issue of this Convertible Note may result in the issue of up to a maximum of 6,000,000 shares.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	The Note will convert to equity either a) after a 12-month period at the Company's option, or b) automatically on the occurrence of a capital raise within that 12-month period raising more than \$1.5mill. Converts at a rate of the lower of \$0.025 per share, or the issue price available should a qualifying capital raise occur.
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Issue of Convertible Notes as per Board Resolution and \$2m convertible note announcement on 10 August 2026.
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial	Should the Notes be converted to ordinary shares at the lowest price, the total ordinary shares that would

¹ The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	be on issue: 345,441,705 ordinary shares Total warrants on issue would remain at: 8,062,512 warrants
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	N/A
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Board resolution The notes were issued in accordance with NZX Listing Rule 4.5.1 to a selected wholesale investor, so that on any Conversion NZX Listing Rule 4.9.1(b)(i) would apply
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	The Convertible Notes issued are: a) Interest bearing for up to 12 months. b) Unsecured. c) Converts to fully paid ordinary shares following either: • a 12-month period at the Company's option, or • automatically on the occurrence of a capital raise within that 12-month period raising more than \$1.5mill. d) Converts at a rate of the lower of \$0.025 per share, or the issue price available should a capital raise occur.
Date of issue/acquisition/redemption	10/08/2026
Section 3: Disclosure required for Placements made under Rule 4.5.1	
Details of the approach in identifying investors who were able to participate in the offer and how their respective allocations in the offer were determined. The explanation must set out the key objectives and criteria the Issuer adopted in the allocation process, whether one of those objectives was a best effort to allocate on a pro rata basis to existing holders of the Issuer's Equity Securities, and any significant exceptions or deviations from those objectives and criteria.	Convertible Notes issued as part of a Convertible Note Facility offered to selected wholesale investors per announcement 10 August 2026. The Board considered funding options and determined that the convertible note facility provides a timely source of growth capital while limiting immediate dilution to existing shareholders. The facility aligns the interests of lenders with the long-term growth of Rua by providing exposure to future equity participation only on conversion.

Section 4: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Paul Naske
Contact person for this announcement	Paul Naske
Contact phone number	021 445 154
Contact email address	Paul.naske@ruabio.com
Date of release through MAP	11/08/2026